• Jebanesan DZP, Illangeswaran RSS, Rajamani BM, Vidhyadharan RT, Das S, Bijukumar NK, Balakrishnan B, Mathews V, Velayudhan SR, Balasubramanian P. Inhibition of NRF2 signaling overcomes acquired resistance to arsenic trioxide in FLT3-mutated Acute Myeloid Leukemia. Ann Hematol. 2024 Apr 17. doi: 10.1007/s00277-024-05742-8. Epub ahead of print. PMID: 38630133.
• Ijee S, Chambayil K, Chaudhury AD, Bagchi A, Modak K, Das S, Benjamin ESB, Rani S, Paul DZ, Nath A, Roy D, Palani D, Priyanka S, Ravichandran R, Kumary BK, Sivamani Y, S V, Babu D, Nakamura Y, Thamodaran V, Balasubramanian P, Velayudhan SR. Efficient deletion of microRNAs using CRISPR/Cas9 with dual guide RNAs. Front Mol Biosci. 2024 Apr 2;10:1295507. doi: 10.3389/fmolb.2023.1295507. PMID: 38628442; PMCID: PMC11020096.
• Rajamani BM, Illangeswaran RSS, Benjamin ESB, Balakrishnan B, Jebanesan DZP, Das S, Pai AA, Vidhyadharan RT, Mohan A, Karathedath S, Abraham A, Mathews V, Velayudhan SR, Balasubramanian P. Modulating retinoid-X-receptor alpha (RXRA) expression sensitizes chronic myeloid leukemia cells to imatinib in vitro and reduces disease burden in vivo. Front Pharmacol. 2023 May 31;14:1187066. doi: 10.3389/fphar.2023.1187066. PMID: 37324449; PMCID: PMC10264673.
• Illangeswaran RSS, Jebanesan DZP, Sivakumar KK, Vidhyadharan RT, Rajamani BM, Janet NB, David E, Velayudhan SR, Mathews V, Balasubramanian P. Chemotherapeutic drugs elicit stemness and metabolic alteration to mediate acquired drug-resistant phenotype in acute myeloid leukemia cell lines. Leuk Res. 2023 May;128:107054. doi: 10.1016/j.leukres.2023.107054. Epub 2023 Mar 3. Erratum in: Leuk Res. 2023 Jul;130:107329. PMID: 36906941.
• Balakrishnan B, Illangeswaran RSS, Rajamani BM, Pai AA, Raj IX, Paul DZ, Lakshmi K, Mani T, Mohanan E, Kulkarni U, Devasia AJ, Fouzia NA, Korula A, Abraham A, Srivastava A, Mathews V, Paczesny S, George B, Balasubramanian P. Prognostic plasma biomarkers of early complications and graft-versus-host disease in patients undergoing allogeneic hematopoietic stem cell transplantation. EJHaem. 2020 Jul;1(1):219-229. doi: 10.1002/jha2.26. Epub 2020 Jun 17. PMID: 32885223; PMCID: PMC7116009.
• Illangeswaran RSS, Das S, Paul DZ, Mathews V, Balasubramanian P. A personalized approach to acute myeloid leukemia therapy: current options. Pharmgenomics Pers Med. 2019 Aug 2;12:167-179. doi: 10.2147/PGPM.S168267. PMID: 31447578; PMCID: PMC6684879.

NIL

Participated

FDP

• One week FDP – Cutting Edge Biotechnology for Precision Medicine  - KL University, Guntur, AP – 09-14-Dec- 2024.

List of abstracts accepted/presented for conferences

ASH 20222 (Online) 

• Efficient Knock-out of Serine Protease Cathepsin G Enhances Chemosensitivity to Cytarabine By Modulating the Cytarabine Metabolic Pathway Genes in Acute Myeloid Leukemia 
• Saswati Das, Raveen Stephen Stallon Illangeswaran, Daniel Zechariah Paul Jebanesan, Esther Sathya Bama Benjamin, Rakhi Thalayatta Vidhyadharan, Vikram Mathews, Shaji Ramachandran Velayudhan, Poonkuzhali Balasubramanian https://doi.org/10.1182/blood-2022-168817 
• Targeting Cholesterol Homeostasis Pathway to Overcome Acquired Cytarabine Resistance in Acute Myeloid Leukemia 
• Saswati Das, Raveen Stephen Stallon Illangeswaran, Daniel Zechariah Paul Jebanesan, Rakhi Thalayatta Vidhyadharan, Vikram Mathews, Shaji Ramachandran Velayudhan, Poonkuzhali Balasubramanian . https://doi.org/10.1182/blood-2022-168776 
• Rxra Overexpression Improves the Sensitivity to Imatinib In-Vitro/in-Vivo By Disrupting the Oxidative Capacity of Chronic Myeloid Leukemia Cells 
• Raveen Stephen Stallon Illangeswaran, Bharathi M Rajamani, Esther Sathya Bama Benjamin, Saswati Das, Daniel Zechariah Paul Jebanesan, Vikram Mathews, Shaji Ramachandran Velayudhan, Poonkuzhali Balasubramanianhttps://doi.org/10.1182/blood-2022-168634 

AACR Annual Meeting 2022 

• Pharmacological inhibition of Nrf2 overcomes acquired resistance to arsenic trioxide in FLT3 mutated acute myeloid leukemia 
• Daniel Zechariah Paul Jebanesan, Raveen Stephen Stallon Illangeswaran, Saswati Das, Rakhi Thalayattu Vidhyadharan, Nayanthara Karpillymoola Bijukumar, Bharathi M. Rajamani, Balaji Balakrishnan, Vikram Mathews, Shaji Ramachandran Velayudhan, Poonkuzhali Balasubramanian https://doi.org/10.1158/1538-7445.AM2022-3977 
• Transcriptomic profiling of in-vitro modeled drug-resistant AML cell lines unravel metabolic and stemness gene signatures 
• Raveen Stephen Stallon Illangeswaran, Daniel Zechariah Paul Jebanesan, Kezia Kanimozhi Sivakumar, Rakhi Thalayattu Vidhyadharan, Vikram Mathews, Shaji Ramachandran Velayudhan, Poonkuzhali Balasubramanian https://doi.org/10.1158/1538-7445.AM2022-3973 
• Inhibition of Lymphoid Enhancer Factor1(LEF1) in acute myeloid leukemia overcomes acquired cytarabine resistance 
• Saswati Das, Raveen Stephen Stallon Illangeswaran, Daniel Zechariah Paul Jebanesan, Rakhi Thalayatta Vidhyadharan, Nayanthara Karpillymoola Bijukumar, Bharathi Murugan Rajamani, Martin Michaelis, Jindrich Cinatl jr., Vikram Mathews, Shaji Ramchandran Velayudhan, Poonkuzhali Balasubramanian  https://doi.org/10.1158/1538-7445.AM2022-6387

Academic Experience:

Assistant Professor 

Department of Biotechnology, SRM-IST, Thiruchirappalli, Tamil Nadu, India (Oct 2024 – Till now)

Industry Experience:

Research Scientist 

Dabur Research Foundation (OECD GLP certified CRO), Sahibabad, Ghaziabad, Uttar Pradesh, India (July 2017-Oct 2018)

Study Director

sa-FORD (OECD GLP certified CRO), Taloja MIDC, Navi Mumbai, Maharashtra, India (July 2015 – July 2017)

Research Experience:

Senior Research Fellow (Indian Council of Medical Research-SRF)

Department of Haematology, Christian Medical College Vellore Ranipet campus, Tamil Nadu, India (Nov 2018 – Sep 2024)

American Association for Cancer Research (AACR)

ID: 1221175

Membership: Associate 

Member Since: 02/17/2022

Expiration Date: 12/31/2025

Projects:

Name: Modulation of chemoresistance in acute myeloid leukemia by Nrf2 and its downstream targets

Funding Agency: Department of Science and Technology

Amount (Lakhs): 45.4

Date of sanction and Duration: September 2018, 36 months

Role: worked as JRF

Name: Can acquired resistance to Arsenic trioxide (ATO) in non-M3 acute myeloid leukemia be overcome by modulating Nrf2 and its downstream targets?

Funding Agency: Christian Medical College Vellore – internal Fluid Grant

Amount (Lakhs): 3

Date of sanction and Duration: April 2021, 24 months

Role: Principal Investigator

Name: Modulation of enzyme carbonyl reductase-1 to overcome acquired resistance to anthracyclines in acute myeloid leukemia

Funding Agency: Christian Medical College Vellore – internal Fluid Grant

Amount (Lakhs): 3

Date of sanction and Duration: February 2022, 24 months

Role: Principal Investigator

Fellowship awarded: 

Name: Modulation of enzyme carbonyl reductase-1 to overcome acquired resistance to anthracyclines in acute myeloid leukemia

Funding Agency: Indian Council of Medical Research

Amount (Lakhs): 16 Lakhs (Stipend – 3 years) 

Date of sanction and Duration: September 2022, 36 months

Role: ICMR-Senior Research Fellow - Principal Investigator